Dopamine control of pyramidal neuron activity in the primary motor cortex via D2 receptors

Clément Vitrac1,2, Sophie Péron1,2, Isabelle Frappé1,2,3, Pierre-Olivier Femagut4,5, Mohamed Jaber1,2,3, Afsaneh Gaillard1,2 and Marianne Benoit-Marand1,2* 

1 Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM, U1084, Poitiers, France  
2 Laboratoire de Neurosciences Expérimentales et Cliniques, Université de Poitiers, Poitiers, France  
3 CHU de Poitiers, Poitiers, France  
4 Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, Bordeaux, France  
5 CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France

The primary motor cortex (M1) is involved in fine voluntary movements control. Previous studies have shown the existence of a dopamine (DA) innervation in M1 of rats and monkeys that could directly modulate M1 neuronal activity. However, none of these studies have described the precise distribution of DA terminals within M1 functional region nor have quantified the density of this innervation. Moreover, the precise role of DA on pyramidal neuron activity still remains unclear due to conflicting results from previous studies regarding D2 effects on M1 pyramidal neurons. In this study we assessed in mice the neuroanatomical characteristics of DA innervation in M1 using unbiased stereological quantification of DA transporter-immunostained fibers. We demonstrated for the first time in mice that DA innervates the deep layers of M1 targeting preferentially the forelimb representation area of M1. To address the functional role of the DA innervation on M1 neuronal activity, we performed electrophysiological recordings of single neurons activity in vivo and pharmacologically modulated D2 receptor activity. Local D2 receptor activation by quinpirole enhanced pyramidal neuron spike firing rate without changes in spike firing pattern. Altogether, these results indicate that DA innervation in M1 can increase neuronal activity through D2 receptor activation and suggest a potential contribution to the modulation of fine forelimb movement. Given the demonstrated role for DA in fine motor skill learning in M1, our results suggest that altered D2 modulation of M1 activity may be involved in the pathophysiology of movement disorders associated with disturbed DA homeostasis.

Keywords: motor cortex, dopamine, mice, unbiased stereology, in vivo electrophysiology

INTRODUCTION

The primary motor cortex (M1) is involved in fine voluntary movements control and in novel motor skill learning (Hosp et al., 2011). It integrates inputs from the premotor cortex and drives excitatory outputs to the spinal cord and the basal ganglia via glutamatergic pyramidal neurons. Dopamine (DA) indirect regulation of motor function through the modulation of basal ganglia activity has been widely described (Alexander et al., 1986; Lang and Lozano, 1998; Murer et al., 2002; Dejean et al., 2012). In addition, neuroanatomical studies have shown the existence of a direct DA innervation from the midbrain to M1 that could directly modulate M1 neuronal activity (Descarries et al., 1987; Gaspar et al., 1991; Raghanti et al., 2008).

Indeed, Gaspar et al. (1991) suggested the presence of such an innervation in the most superficial layers in human M1 using a tyrosine hydroxylase (TH) immunostaining to visualize monoaminergic fibers. In rats, Descarries et al. (1987) showed a dopaminergic innervation in cortical areas such as the cingulate cortex (Cg), or in the deep layers of M1, by using 3H-DA labeling. More recently, Hosp et al. (2011) described in rats direct projections from the ventral tegmental area (VTA) to M1. Although detectable dopaminergic tissue levels can be measured in the motor cortex, this DA innervation remains weak compared with other structures such as the striatum or nucleus accumbens. For instance, Godefroy et al. (1991) showed that DA concentration in the somatomotor cortex is about 50 times lower than in the striatum. However, the functional implication of DA in the motor cortex and other cortical regions, such as the prefrontal and cingulate cortices, has been well documented despite low tissue and extracellular DA levels (Awenowicz and Porter, 2002; Lopez-Avila et al., 2004; Schweimer and Hauber, 2006; Hosp et al., 2009; Molina-Luna et al., 2009). DA acts via five different receptors grouped in two classes, D1-like and D2-like, modulating differentially adenyl cyclase (Jaber et al., 1996). In the last three decades, studies using in situ hybridization (Campos et al., 1990; Mansour et al., 1990; Gaspar et al., 1995; Santana et al., 2009) showed a wide distribution of the DA receptors in rodents. In the cortex, D1 receptors are localized in the layer V1 whereas D2 receptors are localized primarily in the layer V (Weiner et al., 1991; Gaspar et al., 1995), which contains the principal output pathway.
to all other cortical areas and to subcortical targets as the striatum or the pyramidal tract. Taken together, these data suggest that DA receptors could play a direct role in modulating the activity of M1.

Awenowicz and Porter (2002) and Huda et al. (2001) described in vivo, respectively, in rats and cats, that DA application decreases pyramidal neurons activity via both D1 and D2 receptors. More recently, Hosp et al. (2009) showed a transient reduced excitability of M1 mediated by the injection of a D2 antagonist, but not a D1 antagonist, in rats in vivo. Moreover, specific dopaminergic deafferentation of M1 impairs motor skill learning (Hosp et al., 2011) and is associated with decreased long term potentiation (LTP) that is mimicked by reversible blockade of D2 receptors (Molina-Luna et al., 2009). These data suggest that D2 receptors could potentiate basal activity of M1 neurons. Even though a DA projection was reported in M1, the literature lacks quantification of this innervation. Moreover, functional studies are still conflicting regarding the involvement of D1 receptors in the modulation of M1 neuronal activity, and even though the literature agrees on the involvement of D2 receptors, results diverge regarding its excitatory or inhibitory effect on M1 activity. Unfortunately, none of these studies was performed in mice; this is of interest given the substantial number of transgenic mice models targeting the DA system and often used as models of psychiatric or neurodegenerative disorders.

The aim of this study was to assess the neuroanatomical distribution of DA innervation in M1 in mice, and to evaluate the functional role of this innervation on M1 neuronal activity. To this end, we first characterized anatomically DA fiber density in M1 by using the DA transporter (DAT) as a specific marker of DA terminals. In order to precisely quantify this innervation, we performed an unbiased stereological quantification of DAT labeled fibers in M1. Secondly, since all previous studies consensually point to an involvement of D2 receptors in M1, we have tested the direct influence of DA on M1 neuronal activity through this receptor. For that purpose, we performed electrophysiological recordings of M1 neuronal activity while pharmacologically modulating D2 receptors. Our study indicates that DA innervates M1 in mice and is able to enhance the activity of pyramidal neurons in this structure.

MATERIALS AND METHODS

ANIMALS AND SURGERY

All experiments were conducted in accordance with the guidelines of the French Agriculture and Forestry Ministry (decree 87849) and of European Union Directive (2010/63/EU). Adequate measures were taken to minimize animal pain as well as the number of animals used. Female mice C57/BL6 (3–6 months at the time of experiments, Janvier, France) were housed in ventilated cages and kept under a 12 h dark/light cycle. Animals had access to food and water ad libitum.

Before surgery, mice were deeply anesthetized with Urethane (1.8 g/kg) injected intraperitoneally (i.p.) before being secured to a stereotaxic frame (LPC, France) and maintained at 37–38°C with a heating pad. A mouse brain stereotaxic atlas (Paxinos and Franklin, 2001) was used to guide electrode and pipette placements. Throughout the experiment, the efficiency of anesthesia was determined by examining the tail pinch reflex. Additional Urethane (0.25 g/kg, i.p.) was administered when necessary.

ELECTROPHYSIOLOGICAL PROCEDURES

Electrophysiological single unit activity was recorded in M1 using electrodes pulled from borosilicate glass capillaries (GC 150 F, Harvard Apparatus, England) with a P-97 Flaming Brown (Sutter Instrument, USA). The tip of the electrode was broken to a diameter of 2 μm, and the electrode filled with a 0.4 M NaCl solution containing 2.5% neurobionin (Vector Labs, USA). Electrodes had an in vivo resistance of 12–20 MΩ. Recording electrodes were lowered in M1 (1.3–1.5 mm lateral and 1.0–1.5 mm anterior to bregma) at a depth of between 0.65 and 1 mm from the brain surface.

Neuronal activity was amplified 10 times, filtered (bandwith: 300 Hz–10 kHz), and further amplified 100 times (Multiclamp 700-B, Axon Instruments, USA). The signal was digitized (Micro 1401 mk II, Cambridge Electronics Design, England) and acquired on computer using Spike 2 software. Recorded neurons were juxtacellularly labeled with neurobionin (Vector Labs, USA) as described elsewhere (Pinauld, 1996). Briefly, positive 250 ms current pulses were applied at 2 Hz with increasing currents (1–5 nA) until driving cell firing for at least 5 min. Immediately after the neurobionin injection, mice were transcardially perfused with 0.9% NaCl and 4% paraformaldehyde (PFA). Brains were collected and post-fixed for 24 h at 4°C in 4% PFA and cryoprotected overnight in 30% saccharose at 4°C. Serial coronal sections (40 μm) containing M1 were cut using a cryostat (CM 3050 S, Leica, Germany). To reveal neurobionin, sections were rinsed three times in 0.1 M phosphate buffer saline (PBS), processed for 1 h with a blocking solution (3% bovine serum albumine (BSA), 0.3% Triton X-100 in PBS) and incubated overnight at 4°C within Streptavidin Alexa 568 (Invitrogen, USA) diluted 1:800 in PBS containing 3% BSA and 0.3% Triton X-100. Sections were then rinsed three times in PBS before being mounted on gelatin coated-slides, air-dried and coverslipped with DePeX (VWR, USA).

Antidromic stimulation of the striatum ipsilateral to the recording site was performed using a concentric bipolar electrode (SNEX-100, Rhodes Medical Instruments, USA) implanted in the dorsolateral striatum (2 mm lateral and 0.2 mm anterior to the bregma, depth of 1.85 mm from the brain surface). Electrical stimulations (0.5 ms, 600–800 μA) were applied every 5 s using an external stimulator (DS3; Digitimer, England) triggered by a 1401 Plus system (Cambridge Electronic Design, England).

DRUG APPLICATION

Systemic administration of D2 pharmacology was performed through an i.p.-implanted-needle connected to a syringe filled either with a D2 agonist (quinpirole, 0.5 mg/kg, Sigma, USA), D2 antagonist (haloperidol, 0.5 mg/kg, Sigma, USA) or 0.9% NaCl. Drug injections were performed after a 30 min baseline recording and electrophysiological activity was monitored for 45 min following the injection.

Local intracortical drug administration was performed using a glass pipette pulled from a glass capillary (GC 100 FS, Harvard Apparatus, England) filled with either quinpirole 100 μM,
Vitrac et al. Dopamine control of M1 activity

Frontiers in Neural Circuits www.frontiersin.org February 2014 | Volume 8 | Article 13 | 3

quinoiprole 1 μM or artificial cerebrospinal fluid (ACSF) that was lowered close to the tip of the recording pipette. After a 5 min baseline recording, the drug was applied by air pressure and neuronal firing was monitored for another 15 min.

**ANALYSIS OF ELECTROPHYSIOLOGICAL DATA**

The recordings were analyzed offline. Action potential (AP) duration was measured from the time when AP begins to the time when baseline is recovered. In order to assess the pharmacological modulation of neuronal activity, AP firing rate was analyzed before and after pharmacological treatments of 10 min or 1 min durations, respectively, for i.p. and intracortical drug injection. AP durations, neuron responsiveness to striatal stimulation, and firing frequencies were analyzed using Spike 2 7.0 (Cambridge Electronics Design, England). AP firing patterns were analyzed using NeuroExplorer burst analysis (maximum interval to start a burst = 40 ms, maximum interval to end a burst = 10 ms, minimum interval between bursts = 20 ms, minimum duration of a burst = 5 ms and minimum number of spikes in a burst = 2).

**IMMUNOHISTOCHEMICAL PROCEDURES**

Three mice were deeply anesthetized with chloral hydrate (400 mg/kg). They were then perfused transcardiatically with 0.9% NaCl and 1% PFA. Brains were removed, post-fixed in 1% PFA at 4°C for 24 h and cryoprotected overnight in 30% saccharose. Brains were serially cut in six sets of coronal sections (40 μm) using a vibrating microtome (MICROM HM 650 V, Thermo Scientific, France). Free-floating sections were kept at −20°C in glucose 0.19%, ethylene glycol 37.5% and sodium azide 0.25% in PBS 0.05 M.

For each brain, one of the six sets of sections was randomly chosen for DAT immunohistochemical processing. Sections were rinsed three times in 0.1 M Tris-buffered saline (TBS), treated with 0.6% H2O2 in TBS for 15 min, rinsed three times in TBS, and incubated for 90 min in blocking solution (10% donkey serum, 0.3% triton X-100 in TBS). Sections were incubated for 48 h at 4°C using a primary antibody (rabbit anti-DAT, 1:5000, gift from Pr Bertrand Bloch, CNRS UMR5293) diluted in blocking solution. Sections were rinsed three times in TBS and incubated for 1 h in the secondary antibody (donkey anti-rabbit biotin SP, Jackson Immuno Research, USA) diluted 1:500 in TBS containing 5% donkey serum and 0.3% triton X-100. Sections were rinsed three times in TBS, incubated in 0.5% avidin–biotin complex (Vector Labs, USA) in TBS, rinsed three times in TBS and processed with 3-3′-diaminobenzidine (Sigma, USA) and 0.33% H2O2. Sections were mounted, air-dried, and coverslipped in DePeX (VWR, USA).

**STEREOLOGICAL ANALYSIS**

Cingulate cortex was defined anteriorly from 2.58 mm to the bregma to posteriorly −0.82 mm to the bregma, as defined by Paxinos and Franklin (2001). The medial boundaries are defined by the medial line of the brain and the lateral boundaries are defined by the presence of horizontal cortical layers. M1 was defined anteriorly from 1.1 mm bregma to posteriorly −0.94 mm to the bregma from layers I to VI, as defined in a stereotaxic atlas. The relatively narrow layer IV and thick layer V defined the lateral and medial boundaries of M1, and ventral boundaries consisted of the most dorsal part of the corpus callosum. The deep layers of M1 were defined as the most ventral half of M1 (from 500 μm to the surface to the dorsal outline of the corpus callosum), as defined by Lev and White (1997). For the total number of sections containing M1, we sampled every sixth section, starting with a section randomly selected from the first six sections, to generate a set of distributed sections within each sample. After the DAT immunohistochemistry, the average final thickness of the sections was 11.97 ± 0.38 μm (i.e., a shrinkage of ~70% during processing). The stereological analysis used was described previously by Mouton et al. (2002). Each section was scanned by a camera (Orca-R2, Hamamatsu Electronic, Japan) connected to a microscope (DM 5500, Leica, Germany). Then, virtual sphere probes were scanned on the Z axis of M1 and Cg using the Mercator Software (Explora Nova, France). Each sphere was 4 μm radius and contained in a 10 μm × 10 μm square, spacing between each square was 50 μm × 50 μm. Spheres were visualized as a series of concentric circles of changing circumferences upon focusing through the tissue. Finally, the intersections between the outline boundary of the sphere and the fibers were counted at each focal plane. To avoid artifacts due to border effects, upper and lower guard zones of 1 μm were kept for each section. The total length of fibers is calculated according to the following equation:

\[ L = 2 \cdot \sum Q/v \cdot F_1 \cdot F_2 \cdot F_3 \]

where \( L \) = total length of linear feature (in μm), \( \sum Q = \) sum intersections between fibers and spheres, \( F_1 = 1/\text{section sampling fraction} \), \( F_2 = 1/\text{area sampling fraction} \), \( F_3 = 1/\text{thickness sampling fraction} \), \( v/a = \) the ratio of the volume of one sampling box to the surface area of one spherical probe. All values are given as the mean ± SE. Calculated values are corrected for the 70% shrinkage due to section processing.

**DETERMINATION OF THE DOPAMINERGIC FIBERS DISTRIBUTION WITHIN M1**

To determine the rostrocaudal and mediolateral extent of dopaminergic fibers within M1, photomicrographs of sections that previously underwent stereological analysis were used to determine the surface area occupied by DAT labeled fibers. On each section, the results were plotted as the occupied surface in μm² relative to the anteroposterior axis. Measures were performed using ImageJ 1.47v.

**STATISTICAL ANALYSIS**

Statistical analyses were performed using the Mann–Whitney test for independent data, and a two-way ANOVA with Bonferroni posttests when comparing drugs effect over time.

**RESULTS**

**ANATOMICAL DISTRIBUTION OF THE DOPAMINERGIC TERMINALS IN M1**

DA fibers were labeled using DAT immunostaining in order to visualize the dopaminergic innervation in M1 (Figures 1A,B,D) and Cg (Figures 1C,E). Dopaminergic fibers were present in the deep layers of M1. In M1 and Cg, these fibers were long, tortuous and thin with tangles and branches. Stereology was used to precisely evaluate the extent of this innervation.
The mean total length of dopaminergic fibers was 1.89 ± 0.22 mm in M1 and 3.64 ± 0.56 mm in Cg. The dopaminergic innervation density, calculated as the ratio of the total fibers length divided by the volume of the structure, was 0.54 ± 0.01 mm/mm³ in M1 and 2.18 ± 0.20 mm/mm³ in Cg. Thus, according to this stereological approach, DA innervation is 4.4 times higher in Cg than in M1. However, since the dopaminergic fibers in M1 were found mostly in the deep layers (Figure 1D), we performed a stereological quantification of the dopaminergic innervation in the deep layers of M1 defined as the deepest half of M1 (Figure 1B). Total dopaminergic fibers length in the deep layers of M1 was 1.39 ± 0.06 mm. This length is not statistically different from the total length of dopaminergic fibers found in the entire volume of M1 (p = 0.097), confirming our initial observation that dopaminergic terminals in this structure are mostly restricted to the deep cortical layers. The density of DA terminals in the deep layers of M1 was then estimated to 1.38 ± 0.17 mm/mm³. Therefore, when restricting the analysis to the specific region innervated by DA in M1, the dopaminergic innervation density is of the same order of magnitude as in Cg.

To further characterize the neuroanatomical distribution of dopaminergic innervation, we measured the distribution of DA fibers within M1. Differences appeared in the rostrocaudal distribution of DA fibers. Indeed, the area innervated by DA fibers is maximal between 0.2 and 1.10 mm anterior to the bregma (Figure 1F). Furthermore, regarding the mediolateral distribution of dopaminergic fibers in M1 (Figure 1G), we observed that only this area, which corresponds to the forelimb representation area (Tennant et al., 2011), is innervated on the whole mediolateral extent of the structure.

Altogether, these data show that DA innervates the deep layers of mouse M1 with a rostrocaudal gradient. The density of this innervation in M1 deep layers is comparable to that of Cg. It has been well described that DA could modulate Cg neuronal activity (Lopez-Avila et al., 2004; Schweimer and Hauber, 2006). Thus, our results further suggest that the density of DA innervation in M1 deep layers could be sufficient to significantly impact neuronal activity.

**ELECTROPHYSIOLOGICAL CHARACTERISTICS OF RECORDED NEURONS**

We addressed the functional role of D2 receptors on M1 neuronal activity by electrophysiological single unit recordings in anesthetized mice (Figure 2A). Ninety-seven neurons in 56 mice were recorded in deep layers (Figure 2B). In order to investigate D2 effects on M1 output neurons, we focused our experiments on pyramidal neurons, although local-circuit inhibitory neurons are also present (Markram et al., 2004). Previous studies have established the electrophysiological characteristics of pyramidal neurons in rat prefrontal cortex (PFC). Pyramidal neurons exhibit low firing frequencies (between 0.1 and 5 Hz; Hajós et al., 2003) and AP durations above 0.95 ms (Mallet et al., 2005; Tseng et al., 2006). We analyzed these physiological characteristics in the 97 neurons recorded in this study; however, in our conditions, no clear bimodal distribution emerged from this analysis that would have allowed to discriminate between cortical neuronal populations (inhibitory interneurons and excitatory pyramidal neurons; Figure 2C). Regarding firing patterns, we found that 83 neurons presented doublets or triplets (Figure 2A) and a bursty discharge pattern (34.47 ± 2.44% of spikes in burst). In order to determine an inclusion criteria specific to our experimental conditions, we analyzed the electrophysiological characteristics of neurons identified as projection neurons by their antidromic response to the stimulation of the ipsilateral striatum (Figure 3A). Neurons that presented antidromic responses were considered as pyramidal. We recorded nine antidromically responding neurons and four neurons that did not respond to the striatal stimulation. Responsive and non-responsive neurons were statistically different regarding their firing pattern (p < 0.01). Indeed, all neurons responding to the antidromic stimulation presented at least 25% of their spikes in bursts (ranging from 25 to 68%) whereas the non-responding neurons presented at most 8.8% of their spikes in bursts (ranging from 0 to 8.8%; Figure 3B). Thus, in our experimental conditions, the percentage of spikes in bursts is the best electrophysiological characteristic to consider a neuron as a pyramidal one. Using this characteristic as a criterion, 30 neurons presenting at least...
Vitrac et al. Dopamine control of M1 activity

AP firing rate of putative pyramidal neurons in the deep layers dol (0.5 mg/kg; n (i.p.) injections of quinpirole (0.5 mg/kg; via the basal ganglia. To avoid the indirect network effects of haloperidol on AP firing rate. D2 antagonist haloperidol. We first performed intraperitoneal injections of haloperidol 100 μM; quinpirole 1 μM or ACSF (Figures 5A,B). Due to absence of significant modifications after i.p. injections of haloperidol, we did not test the pyramidal neuron responses to intracortical injections of the D2 antagonist. Consistent with the results obtained after i.p. injections, local D2 receptor activation by quinpirole (100 or 1 μM) enhanced putative pyramidal neurons firing rate (respectively: Two way ANOVA \( F_{(4,28)} = 5.24, p < 0.001; \) Two way ANOVA \( F_{(4,36)} = 3.98, p < 0.01 \). Quinpirole (1 μM) also increased spike firing rates from 1.53 ± 0.44 Hz to 2.47 ± 0.62 Hz (Figure 5C). Furthermore, analysis of neuronal AP firing pattern revealed that the number of bursts, but not the percentage of spikes in burst, was increased by D2 receptors activation (data not shown). These results indicate that DA can enhance pyramidal neuron firing rates, but does not modulate firing patterns. Taken together, these results show that DA exerts a direct role on M1 neuronal activity by enhancing neuronal firing rate via D2 receptors.

**DISCUSSION**

In this study, we demonstrated for the first time in mice that DA innervates the deep layers of M1. We also established that these fibers target preferentially the forelimb representation area of M1. To address the functional role of DA on M1 neuronal activity, we performed electrophysiological recordings of single neuron activity in vivo and pharmacologically modulated D2 receptors. We demonstrated that D2 receptor activation by quinpirole enhanced pyramidal neuron spike firing rates. Our results also show that this increase was not due to an extracortical network effect, but is locally mediated in M1.

**ANATOMICAL CHARACTERIZATION OF DA INNERVATION OF M1 IN MICE**

Although TH immunolabeling is commonly used to reveal dopaminergic fibers (Gaspar et al., 1991; Busceti et al., 2008), TH is an enzyme common to all catecholamines synthesis, and such does not allow one to distinguish between adrenergic and dopaminergic fibers. Thus, to specifically target dopaminergic fibers, we used a DAT antibody. DAT distribution has already been shown to be restricted to dopaminergic regions (Ciliax et al., 1995). Our results in mice showing the existence of a dopaminergic innervation of M1 are in accordance with previous studies conducted in different species including rat (Descarries et al., 1987), monkey (Raghanti et al., 2008) and human (Gaspar et al., 1991; Raghanti et al., 2008). Moreover, this study provides for the first time a precise and direct quantification of this innervation in M1 and Cg using an unbiased stereological approach. This quantification allowed us to precisely detail the distribution of DA fibers at different levels of M1. Our data complement previous observations by showing that the density of dopaminergic innervation is similar in the deep layers of M1 and in Cg. The functional significance of DA in Cg has been well established (Lopez-Avila et al., 2004). Previous studies showing the existence of D1 and D2 receptors in M1 (Camps et al., 1990; Mansour et al., 1990; Gaspar et al., 1995; Santana et al., 2009), together with our present results, provide anatomical evidence

**FIGURE 2 | Electrophysiological characteristics of M1 neurons.**

(A) Representative electrophysiological trace of a cortical neuron. Note the presence of triplet of spikes (black arrows). The inset represents the action potential shape (averaged over 5 min recording), the action potential duration is measured between the two dashed lines. (B) Schematic representation of the distribution of recorded neurons in M1 1.4 mm anterior to Bregma, neurobiotine labeled neurons (red dots) and non labeled neurons (black dots). Photomicrograph shows a representative example of neurobiotine labeled neuron. Scale bar represents 20 μm. (C) Distribution of the mean frequency (Hz) and AP duration (ms).

15% spikes in burst were included in the study and referred to as "putative pyramidal neurons".

**EFFECTS OF Dopamine D2 RECEPTOR AGONIST AND ANTAGONIST ON PUTATIVE PYRAMIDAL NEURON ACTIVITY IN M1 IN VIVO**

To study the effects of DA on M1 neuronal activity, we recorded AP firing rate of putative pyramidal neurons in the deep layers of M1 and their response to the D2 agonist quinpirole or the D2 antagonist haloperidol. We first performed intraperitoneal (i.p.) injections of quinpirole (0.5 mg/kg; n = 5), haloperidol (0.5 mg/kg; n = 5) or saline 0.9% (n = 5; Figure 4). D2 receptor activation by quinpirole enhanced putative pyramidal neurons firing rate by more than 200% (from 1.46 ± 0.39 Hz to 3.44 ± 0.81 Hz, two way ANOVA \( F_{(2,60)} = 15.11, p < 0.001 \). There was no statistically significant effect of D2 receptors blockade by haloperidol on AP firing rate.

These effects could be due to a network effect, particularly via the basal ganglia. To avoid the indirect network effects of DA and address the direct effect of D2 activation on M1 activity, we performed intracortical injections of quinpirole 100 μM, quinpirole 1 μM or ACSF (Figures 5A,B). Due to absence of significant modifications after i.p. injections of haloperidol, we did not test the pyramidal neuron responses to intracortical injections of the D2 antagonist. Consistent with the results obtained after i.p. injections, local D2 receptor activation by quinpirole (100 or 1 μM) enhanced putative pyramidal neurons firing rate (respectively: Two way ANOVA \( F_{(4,28)} = 5.24, p < 0.001; \) Two way ANOVA \( F_{(4,36)} = 3.98, p < 0.01 \). Quinpirole (1 μM) also increased spike firing rates from 1.53 ± 0.44 Hz to 2.47 ± 0.62 Hz (Figure 5C). Furthermore, analysis of neuronal AP firing pattern revealed that the number of bursts, but not the percentage of spikes in burst, was increased by D2 receptors activation (data not shown). These results indicate that DA can enhance pyramidal neuron firing rates, but does not modulate firing patterns. Taken together, these results show that DA exerts a direct role on M1 neuronal activity by enhancing neuronal firing rate via D2 receptors.
Vitrac et al. Dopamine control of M1 activity

FIGURE 3 | Electrophysiological characteristics of antidromically identified neurons. (A) Representative electrophysiological recording trace of a cortical neuron responding to the striatal stimulation by an antidromic spike (left). The occurrence of a spontaneous AP just before the stimulation collides with the antidromic spike resulting in the absence of the antidromic response after the stimulation (right). (B) Neurons were divided in two groups according to their response (black dots) or not (white dots) to the striatal stimulation, the graphs show the individual data (large dots) as well as the mean ± SEM of electrophysiological characteristics: Mean frequency (Hz), AP duration (ms) and percentage of spikes included in a burst (%). **p < 0.01.

FIGURE 4 | D2 modulation of M1 neuronal activity. (A) Effect of a peripheral injection of D2 agonist quinpirole (n = 5, black) or D2 antagonist haloperidol (n = 6, grey) or NaCl 0.9% (n = 5, white) on putative pyramidal neurons firing frequency. (B) Individual responses of putative pyramidal neurons to the D2 agonist. **p < 0.01; ***p < 0.001.

suggesting that DA can exert a direct influence onto M1 neuronal activity.

DA MODULATION OF M1 NEURONAL ACTIVITY IN VIVO

We investigated the hypothesis that DA directly modulates M1 activity using single unit electrophysiological recordings in anesthetized mice and showed that DA has a direct influence on putative pyramidal neuron activity in M1. In our experiments, D2 receptor activation increased neuronal spike firing rate by enhancing the number of spikes, but not the percentage of spikes in bursts. Our results are consistent with a previous study showing in rats that a local injection of haloperidol induced an increase of motor threshold and a reduced size of motor maps, suggesting an excitatory role of D2 receptor activation in M1 (Hosp et al., 2009).

Awenowicz and Porter (2002) previously reported the involvement of the two types of DA receptors in a synergistic manner in rat motor cortex. Their study showed a global inhibitory effect in pyramidal neuron activity following iontophoretic DA (0.1 M) administration. The discordance between their results and ours could be explained by the difference in the local injection procedure (iontophoresis versus pressure ejection). Although this study showed a DA effect on M1 electrophysiological activity, one must consider the possible electrophysiological perturbations in neuronal activity induced by iontophoresis injection. Indeed, it was recently shown that high current injections near neurons can lead to decreased neuronal firing rates (Moore et al., 2011).

Our results showing enhanced putative pyramidal neuron activity after D2 receptor activation are consistent with the finding that quinpirole acting on D2 receptors increases the excitability of layer V pyramidal neurons in the PFC of adult mice (Gee et al., 2012). This study, performed in brain slices, demonstrated an excitatory effect of D2 receptor activation on PFC pyramidal neurons by the induction of a calcium-channel-dependent after-depolarization.

However, other scenarios might also contribute to the effects of D2 agonists on motor cortex excitability. On one hand, DA effects on putative pyramidal neuron activity might be local, but indirect via the modulation of cortical inhibitory interneurons. Indeed, in primate PFC, DA axons establish direct contacts with interneurons expressing parvalbumin (Sesack et al., 1998). More recently, Santana et al. (2009) reported that inhibitory interneurons in rats PFC express D1 and D2 receptors. Moreover, electrophysiological studies from mice and rat PFC slices suggest that D2 receptor activation inhibits GABA interneurons (Xu and Yao, 2010), resulting in a decreased GABA release probability and
a reduction of inhibitory postsynaptic currents (Seamans et al., 2001). Although these studies were conducted in prepubertal animals, they suggest that D2 receptor agonists could decrease the activity of inhibitory interneurons, thus indirectly enhancing pyramidal neuron activity.

On the other hand, DA effects observed in this study might be exerted directly on pyramidal neurons. Indeed, a recent study in prepubertal animals, they suggest that D2 receptor agonists could decrease the activity of inhibitory interneurons, thus indirectly enhancing pyramidal neuron activity.

In conclusion, our study provides for the first time a precise description of the dopaminergic projections to M1 in mice, with a stereological quantification of DA innervation density and fiber distribution within M1. In addition, we show an increased putative pyramidal neurons firing activity induced by local D2 agonist. The exact mechanisms of this modulation remain to be elucidated and the role of D1 receptors has yet to be considered. Nevertheless, these results constitute a new step towards understanding the mechanisms by which DA modulates M1 activity and suggest that altered local D2 modulation may be involved in pathophysiological conditions associated with disturbed DA homeostasis.

ACKNOWLEDGMENT
This work was funded by grants from the Fondation de France, FEDER No. 33552 and the CPER 5.

REFERENCES
Alexander, G. E., Delong, M. R., and Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357–381. doi: 10.1146/annurev.ne.09.030186.002041
Awendowicz, P. W., and Porter, L. L. (2002). Local application of dopamine inhibits pyramidal tract neuron activity in the rodent motor cortex. J. Neurophysiol. 88, 3439–3451. doi: 10.1152/jn.00787.2002
Busceti, C. L., Biagioni, F., Mastroiacovo, F., Bucci, D., Lenzi, P., Pasquali, L., et al. (2008). High number of striatal dopaminergic neurons during early postnatal development: correlation analysis with dopaminergic fibers. J. Neural Transm. 115, 1375–1383. doi: 10.1007/s00702-008-0112-x

Frontiers in Neural Circuits www.frontiersin.org February 2014 | Volume 8 | Article 13 | 7
Dopamine control of M1 activity

Vitrac et al.

Camp, K., Kelly, P. H., and Palacios, J. M. (1990). Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. J. Neural. Transm. Gen. Sect. 80, 105–127. doi: 10.1007/BF01257077

Ciliax, B. J., Heilman, C., Demchynshyn, L. L., Pristupa, Z. B., Ince, E., Hersch, S. M., et al. (1995). The dopamine transporter: immunohistochemical characterization and localization in brain. J. Neurosci. 15, 1714–1723.

Dejean, C., Nadjar, A., Le Moine, B., Boulac, B., Gross, C. E., and Boraud, T. (2012). Evolution of the dynamic properties of the cortex–basal ganglia network after dopaminergic depletion in rats. Neurobiol. Dis. 46, 402–413. doi: 10.1016/j.nbd.2012.02.004

Descaries, L., Lemay, B., Doucet, G., and Berger, B. (1987). Regional and laminar density of the dopamine innervation in adult rat cerebral cortex. Neuroscience 21, 807–824. doi: 10.1016/0306-4522(87)80038-8

Fellows, S. J., and Noth, J. (2004). Grip force abnormalities in de novo Parkinson’s disease. Mov. Disord. 19, 560–565. doi: 10.1002/mds.10710

Gaspar, P., Bloch, B., and Le Moine, C. (1995). D1 and D2 receptor gene expression in rat frontal cortex: cellular localization in different classes of effferent neurons. Eur. J. Neurosci. 7, 1050–1063. doi: 10.1111/j.1460-9568.1995.tb01920.x

Gaspar, P., Duyckaerts, C., Alvarez, C., Javoy-Agid, F., and Berger, B. (1991). Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Mov. Disord. 6, 793–807. doi: 10.1002/mds.10715

Gaspar, P., Duyckaerts, C., Alvarez, C., Javoy-Agid, F., and Berger, B. (1991). Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Mov. Disord. 6, 793–807. doi: 10.1002/mds.10715

Hosp, J. A., Molina-Luna, K., Hertler, B., Atiemo, C. O., and Luft, A. R. (2009). Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Mov. Disord. 15, 1714–1723.

Javoy-Agid, F., Bensimon, G., and Lasek, G. (1991). Selective vulnerability of certain layer V pyramidal neurons in prefrontal cortex of Alzheimer’s disease. J. Neurosci. 11, 4959–4977. doi: 10.1523/JNEUROSCI.0583-11.2012

Koch, C., and Davis, J. (1981). Temporal coding of sensory information in the thalamus and cortex of the cat. In: Sensory Processing in the Central Nervous System, eds D. C. Weiskrantz (Oxford: Clarendon Press). 1–27.

Lang, A. E., and Lozano, A. M. (1998). Parkinson’s disease. First of two parts. N. Engl. J. Med. 339, 1044–1053. doi: 10.1056/NEJM199808133391506

Lev, D. L., and White, E. L. (1997). Organization of pyramidal cell apical dendrites and composition of dendritic clusters in the mouse: emphasis on primary motor cortex. Eur. J. Neurosci. 9, 280–290. doi: 10.1111/j.1460-9586.1997.tb01388.x

Mansour, A., Meador-Woodruff, J. H., Bunzow, J. R., Civelli, O., Akil, H., and Duman, S. R. (1990). Dopaminergic inhibition of cortical pyramidal neurons. Brain Res. 519, 258–260. doi: 10.1016/0006-8993(90)90255-1

Moore, A. R., Zhou, W. L., Potapenko, E. S., Kim, E. I., and Antic, S. D. (2011). Brief dopaminergic stimulations produce transient physiological changes in prefrontal pyramidal neurons. Brain Res. 1370, 1–15. doi: 10.1016/j.brainres.2010.11.011

Morgante, F., Espay, A. J., Gunraj, C., Lang, A. E., and Chen, R. (2006). Motor cortex plasticity in Parkinson’s disease and levodopa-induced dyskinesias. Brain 129, 1059–1069. doi: 10.1093/brain/awl031

Mouton, P. R., Gokhale, A. M., Ward, N. L., and West, M. J. (2002). Stereological length estimation using spherical probes. J. Microsc. 206, 54–64. doi: 10.1046/j.1365-2818.2002.00106.x

Murer, M. G., Tseng, K. Y., Kasanetz, F., Belluscio, M., and Riquelme, L. A. (2002). Cortical dopaminergic innervation among humans, chimpanzees, and macaque monkeys: a comparative study. Neuroscience 155, 203–220. doi: 10.1016/s0096-3932(03)00758-4

N-Acetyltransferase activity in permanent dopaminergic and noradrenergic neurons. J. Neurosci. Methods 71, 1–8. doi: 10.1016/s0165-0270(96)00101-0

Pekanovic, A., Rohrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, M. S., et al. (2009). Dopamine D1 and D2 receptors in the brain of several mammalian species. J. Neurosci. 29, 13–24. doi: 10.1001/1.e7082. PLoS ONE 4:e7082. doi: 10.1371/journal.pone.0007082

Copyright © 2014 Vitrac, Péron, Frappe, Fernagut, Jaber, Gaillard and Benoit-Marand. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.